MT Newswires10d agobullish
UBS Adjusts Price Target on Biogen to $300 From $270, Keeps Buy RatingNews
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
107last 24h
3127last 7d
512● bullish (7d)
311● bearish (7d)
227publishers
MT Newswires10d agobullish
RBC Raises Price Target on Biogen to $272 From $256, Keeps Outperform RatingMT Newswires75d agobullish
Veeva's Vault CRM Wins Reinforce Market-Leader Status Ahead of Earnings, Truist SaysInvesting.com87d agobullish
Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuationInvesting.com102d agobullish
Biogen Q2 revenue, adjusted EPS beat estimates as growth portfolio lifts salesInvesting.com118d agobullish
Truist upgrades Biogen to Buy on Alzheimer’s, pipeline optimism ahead of key dataBarrons.com118d agobullish
Biogen Stock Is Upgraded to Buy Ahead of Key Alzheimer’s Drug Study Details